What are your thoughts, Sushi?
I suspect the following. Cvm can identify individuals that would benefit from Multikine across both treatment groups. Cvm also knowns which individuals were improving prior receiving chemo and would have faired well if not for the chemo.
Given the above, cvm is either:
1. (Optimistic) applying for a license to treat everyone that can be identified as receptive to treatment potentially even replacing chemo, but that involves a difficult discussion with fda that takes time.
2. (Realistic) applying to treat only the subgroup w/o chemo but the method to identify the target group of patients in advance is arguable.
News 
Market Data 
Discover 
